The heart of insitro’s strategy is the development of novel, cutting edge methods in machine learning and high-throughput biology that address key bottlenecks in the drug development pipeline. To accomplish that, we are putting together a team of life scientists with expertise in cellular and biochemical assays. In this role, you will lead projects focused on identifying and validating intermediate phenotypes of disease processes. In collaboration with the Functional Genomics, Disease Modelling and Process Engineering groups, you will develop liver disease phenotypic assays to enable screening of chemical libraries and genetically modified cells. There will be the opportunity for career development and over time taking on the responsibility of target prosecution and the establishment of validated biomarker assays that can be used for IND applications and/or clinical development programs.
Your primary duties will be to:
You will be joining a biotech startup that has long-term stability due to significant funding, but yet is very much in formation. A lot can change in this early and exciting phase, providing many opportunities for significant impact. You will work closely with a very talented team, learn a broad range of skills, and help shape insitro’s culture, strategic direction, and outcomes. Join us, and help make a difference to patients!
Benefits at insitro
insitro is a data-driven drug discovery and development company using machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company is applying state-of-the-art technologies from bioengineering to create massive data sets that enable the power of modern machine learning methods to be brought to bear on key bottlenecks in pharmaceutical R&D. The resulting predictive models are used to accelerate target selection, to design and develop effective therapeutics, and to inform clinical strategy. insitro was launched in 2018 with a Series A of $100M funded by top investors including a16z, Arch Venture Partners, Foresite Capital, GV, and Third Rock Ventures. In 2019 the company announced a collaboration with Gilead Sciences in the area of NASH, a collaboration with BMS in the area of ALS, and in mid 2020, announced a Series B financing of $143M including current investors and new investors Canada Pension Plan Investment Board (CPP Investments), T. Rowe Price, BlackRock, Casdin Capital and other leading investors. The company is located in South San Francisco, CA. For more information about insitro, please visit the company’s website at www.insitro.com
Your application was submitted successfully.